Literature DB >> 7636553

Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin.

J L Abbruzzese1, M C Abbruzzese, R Lenzi, K R Hess, M N Raber.   

Abstract

PURPOSE: Diagnostic strategies designed to identify the underlying primary malignancies in patients with unknown primary tumors (UPTs) have relied on retrospective analyses. We analyzed 879 consecutive patients referred with suspected UPTs to determine the yield and cost of a limited diagnostic evaluation, assess the contribution of specific studies to diagnosis, and analyze the survival patterns of patients in whom the primary tumor was diagnosed. PATIENTS AND METHODS: Data from patients with a suspected UPT were entered into a computerized data base, and the patients underwent a predefined limited diagnostic evaluation. Primary malignancies were diagnosed by pathologic review alone or by pathologic criteria plus a physical or radiographic finding. Survival was measured from diagnosis, estimated using the Kaplan-Meier method, and compared using the Cox-Mantel log-rank test.
RESULTS: A primary tumor was found in 179 of 879 patients (20%). The survival duration of patients in whom the primary tumor was diagnosed was superior to that of patients in whom the primary tumor remained unknown. Specific patient subsets contributed most to the improved survival duration of the group in which the primary tumor was found, including lymphoma patients diagnosed solely by pathologic criteria and female patients with primary breast or ovarian cancer. The cost of diagnosis was mostly due to the extensive use of computed tomography. Except for ovarian cancer, computed tomography rarely identified treatable primary tumors.
CONCLUSION: The limited diagnostic evaluation used in this study identified patients with treatable malignancies and increased the survival duration of a population of suspected UPT patients. Primary malignancies with the best survival can be diagnosed through careful pathologic review and focused evaluations for breast and ovarian cancer in women.

Entities:  

Mesh:

Year:  1995        PMID: 7636553     DOI: 10.1200/JCO.1995.13.8.2094

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  64 in total

1.  Whole-body turbo STIR MR imaging: controversies and avenues for development.

Authors:  Eoin Kavanagh; Clare Smith; Stephen Eustace
Journal:  Eur Radiol       Date:  2003-04-25       Impact factor: 5.315

2.  Orbital metastases: diagnosis and course.

Authors:  D H Char; T Miller; S Kroll
Journal:  Br J Ophthalmol       Date:  1997-05       Impact factor: 4.638

3.  MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin.

Authors:  Manuela Ferracin; Massimo Pedriali; Angelo Veronese; Barbara Zagatti; Roberta Gafà; Eros Magri; Maria Lunardi; Gardenia Munerato; Giulia Querzoli; Iva Maestri; Linda Ulazzi; Italo Nenci; Carlo M Croce; Giovanni Lanza; Patrizia Querzoli; Massimo Negrini
Journal:  J Pathol       Date:  2011-06-01       Impact factor: 7.996

4.  Tumor-marker analysis and verification of prognostic models in patients with cancer of unknown primary, receiving platinum-based combination chemotherapy.

Authors:  Kan Yonemori; Masashi Ando; Taro Shibata; Noriyuki Katsumata; Koji Matsumoto; Yasuhiro Yamanaka; Tsutomu Kouno; Chikako Shimizu; Yasuhiro Fujiwara
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-22       Impact factor: 4.553

5.  Prognostic and diagnostic accuracy of [18F]FDG-PET/CT in 190 patients with carcinoma of unknown primary.

Authors:  Pavel Fencl; Otakar Belohlavek; Magdalena Skopalova; Monika Jaruskova; Iva Kantorova; Katerina Simonova
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06-01       Impact factor: 9.236

6.  Imprint cytological diagnosis of colonic adenocarcinoma metastatic to liver.

Authors:  Shashikant Adlekha; Tandra Chadha; Prasad Krishnan; B Sumangala
Journal:  Malays J Med Sci       Date:  2013-07

7.  Identification of tissue of origin in carcinoma of unknown primary with a microarray-based gene expression test.

Authors:  Federico A Monzon; Fabiola Medeiros; Maureen Lyons-Weiler; W David Henner
Journal:  Diagn Pathol       Date:  2010-01-13       Impact factor: 2.644

8.  A suggested guiding panel of seromarkers for efficient discrimination between primary and secondary human hepatocarcinoma.

Authors:  Nabil Mohie Abdel-Hamid; M M Abouzied; M H Nazmy; M A Fawzy; A S Gerges
Journal:  Tumour Biol       Date:  2015-09-19

9.  Metastases in the Absence of a Primary Tumor: Advances in the Diagnosis and Treatment of CUP Syndrome.

Authors:  Kai Neben; Gerdt Hübner; Gunnar Folprecht; Dirk Jäger; Alwin Krämer
Journal:  Dtsch Arztebl Int       Date:  2008-10-24       Impact factor: 5.594

10.  Development and validation of a bedside score to predict early death in cancer of unknown primary patients.

Authors:  Nicolas Penel; Sylvie Negrier; Isabelle Ray-Coquard; Charles Ferte; Patrick Devos; Antoine Hollebecque; Michael B Sawyer; Antoine Adenis; Pascal Seve
Journal:  PLoS One       Date:  2009-08-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.